Related Experiment Videos

[Candida albicans prosthetic valve endocarditis. Two cases]

Hatem Bouraoui1, Abdallah Mahdhaoui, Jilani Zaaraoui

  • 1Service de Cardiologie, Hôpital Farhat-Hached, 4000 Sousse, Tunisie. hatembouraoui@yahoo.fr

Annales De Medecine Interne
|September 10, 2002
PubMed

Insights

Candida albicans prosthetic valve endocarditis (PVE) is rare but serious. Early diagnosis and antifungal therapy are crucial for managing this life-threatening condition.

Area of Science:

  • Infectious Diseases
  • Cardiology
  • Mycology

Background:

  • Prosthetic valve endocarditis (PVE) caused by Candida albicans is a rare but severe clinical entity.
  • Fungal endocarditis poses diagnostic and therapeutic challenges, particularly in prosthetic heart valves.

Observation:

  • Two cases of Candida albicans PVE are presented, confirmed by prosthetic valve cultures.
  • Case 1: Patient died from cerebral bleeding due to mycotic aneurysms 20 days post-surgery.
  • Case 2: Patient survived 8 months post-aortic valve replacement with prolonged antifungal treatment.

Findings:

  • Candida albicans PVE requires prompt identification and aggressive management.
  • Successful outcomes may depend on early diagnosis, appropriate antifungal therapy, and surgical intervention.
  • Mycotic aneurysms are a serious complication, leading to high mortality.

Implications:

  • Highlights the critical need for heightened clinical suspicion for fungal PVE in at-risk patients.
  • Emphasizes the importance of prolonged antifungal therapy and multidisciplinary management strategies.
  • Suggests a need for further research into optimal diagnostic and treatment protocols for Candida PVE.

Related Concept Videos